![Steen Klysner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steen Søren Klysner currently works at ZYNEYRO ApS, as Chief Executive Officer from 2023.
Dr. Klysner also formerly worked at Nordic Vaccine A, as Chief Executive Officer, ExpreS2ion Biotechnologies ApS, as Chief Executive Officer, Expres2ion Biotech Holding AB, as Chief Executive Officer, Amarna Therapeutics BV, as Chief Executive Officer from 2020 to 2023, MinervaX ApS, as Chairman, Pharmexa A, as Director & Vice President, Nykode Therapeutics ASA, as Director, Novo Nordisk A, as Principal, ALK-Abello A, as Vice President-Preclinical Research & Development, and Allergopharma Srl, as Vice President-Research & Development.
Dr. Klysner received his doctorate degree from Technical University of Denmark and undergraduate degree and graduate degree from the University of Copenhagen.
| Sociétés | Poste | Début |
|---|
| Sociétés | Poste | Fin |
|---|---|---|
Amarna Therapeutics BV
 Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Develops gene and immune-therapies | Directeur Général | 07/06/2023 |
| EXPRES2ION BIOTECH HOLDING AB | Directeur Général | 20/12/2019 |
Allergopharma Srl
 Allergopharma Srl Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and chemicals products | Corporate Officer/Principal | - |
ExpreS2ion Biotechnologies ApS
 ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology Operates as a biotech company which engages in the field of protein production in Drosophila Schneider-2 cells | Directeur Général | - |
Nordic Vaccine A/S
 Nordic Vaccine A/S Pharmaceuticals: MajorHealth Technology Researches, develops and specializes in adjuvants and drug delivery development | President | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 12 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
ALK-Abello A/S
 ALK-Abello A/S Pharmaceuticals: MajorHealth Technology Develops and produces, markets products for diagnosing, treating allergies, allergic asthma & acute anaphylactic reactions | Health Technology |
Technical University of Denmark
 Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nordic Vaccine A/S
Nordic Vaccine A/S Pharmaceuticals: MajorHealth Technology Researches, develops and specializes in adjuvants and drug delivery development | Health Technology |
Nykode Therapeutics ASA
 Nykode Therapeutics ASA Pharmaceuticals: MajorHealth Technology Develops vaccines and immunotherapy against infectious diseases and cancer | Health Technology |
Minervax ApS
 Minervax ApS Pharmaceuticals: MajorHealth Technology Develops prophylactic vaccines for pregnant women and older adults | Health Technology |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology Operates as a biotech company which engages in the field of protein production in Drosophila Schneider-2 cells | Health Technology |
Allergopharma Srl
Allergopharma Srl Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and chemicals products | Health Technology |
Expres2ion Biotech Holding AB
 Expres2ion Biotech Holding AB BiotechnologyHealth Technology Engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer | Health Technology |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Develops gene and immune-therapies | Health Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
